as of 12-05-2025 4:00pm EST
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 1.4B | IPO Year: | 1995 |
| Target Price: | $43.60 | AVG Volume (30 days): | 667.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.91 - $55.63 | Next Earning Date: | 11-21-2025 |
| Revenue: | $593,821,000 | Revenue Growth: | -9.52% |
| Revenue Growth (this year): | 6.13% | Revenue Growth (next year): | 5.02% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
President and CEO
Avg Cost/Share
$29.41
Shares
316
Total Value
$9,293.56
Owned After
105,979.78
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Marotta John | AZTA | President and CEO | Sep 10, 2025 | Sell | $29.41 | 316 | $9,293.56 | 105,979.78 |
See how AZTA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "AZTA Azenta Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.